Stats

P1 NumPyseed9091230,20000IIDpaths20draws from actual3returns at187.22USD reproduces prior1772 PnL2.5/50/97.5[-93.669315,-30.013809,79.173517],loss81.26%. P2 Operator-censoredN3 and unsupported stationarity mean this is a sensitivity illustration, not forecast, independent evidence or15minute stop-exit odds. P3 Frozenholdout mean-.094356461% implies-.176654USD per fullfund deployment, excludes fixed costs. Conclusion actual proposednotional0; freshsimulation cannot manufactureedge. Source observation18615/query_trades fund=quant and original1642 https://runway.adityaperswal.workers.dev/data/stock-bars .

P1 All3 direct PDFs21:02–03 same SHA as19:43, and bounded issuer release links unchanged. Interested sponsors closest to evidence; file identity is not proof no other news. P2 Prior reviewed TYRA8/14primaryCR versus8/8subgroupORR and modeledHRs, IRDnonprespecified highlighted loci versus prospective prespecified pivotal, INBX efficacy/safetydenominators still prevent clinical-to-value calibration. These are inherited reviewed qualifications, not new full reread. P3 Controlled durability, regulatory/payer success, manufacturing and shareholder cash after financing remain uncalibrated; no approval probability/DCF invented. Counterexample genuine clinical activity can create value, but unchanged deck does not measure mispricing. Sources observation18616 https://ir.tyra.bio/static-files/e2ddb459-375e-49f8-a9ae-a5303c6d8e3a ; https://ir.opusgtx.com/presentations ; https://inhibrx.com/hexagon-slides/ .

P1 Explicit t<20UTC filter yields19:59TYRA22.015/IRD5.72/INBX112.61, regularcounts383/390/294, absent7/0/96 not filled. API endpoint20UTC included20:00bar so endpoint name is not sufficient. P2 Provider daily22.01/5.73/112.86 differs-.022712/+.174825/+.222005%; daily opens18.94/5.31/117.38 differ minute18.66/5.30/117.38. Aggregate eligibility/auction identification unresolved; not proof of error or executable auction. P3 TYRA+17.9796%open yet-17.6394%prior,IRD+31.7972%prior yet-19.0948%high,INBX-4.0637%open/-12.3930%high. P4 IEXquotes timestamp20:00 staleat21:03, spreads3336/2943bps andINBXask0: no current fills. Conclusion no overnight entry without tested net edge and executable quotes. Counterargument rebounds may persist, but not estimated. Sources observation18612–14 https://runway.adityaperswal.workers.dev/data/stock-bars and /data/stock-snapshots.

P1 Original backtest1642 reread, not rerun: 2021–25 holdout252 after2016–20train, cashmean-.094356461%,p45.634920635%,W.490801991%,L.585547862%,return-21.631824%,DD25.206217%;stress-52.657075%. P2 Own three operator-liquidated trades recomputed p1/3,W7.939941%,L5.261432%,mean-.860974%; intended4–6week horizons censored, quote benchmarks absent so slippage/stop-hit odds unidentified. P3 max(0,.25*(p-(1-p)*L/W))=0 for both. Counterexample2026extensionN28+2.31% exists but stress-3.26% and cannot replace holdout. Conclusion zero allocation; no clinical-response proportion transferred to stock win rate. Observation18615; source https://runway.adityaperswal.workers.dev/data/stock-bars and query_trades fund=quant.

Start state: Quant187.22 cash, account850.99; goal repeatable positive net returns; binding constraint independently validated edge. P1 Original1642 holdout252 loses21.63%, stress52.66%, quarterKelly0; no new fit. P2 Own3 censored liquidations also quarterKelly0. P3 Three unchanged clinical PDFs and mixed current price paths do not create an independently tested clinical-stock rule. P4 IEX spreads and91 missing INBX minutes retain execution uncertainty. Conclusion no PROPOSE/EXIT/ADJUST/FUND. Validity: mandatory net-edge gate implies zero size; soundness conditional on data/cost assumptions, not a claim every quant strategy fails. Strong counterargument continued clinical drift may occur; to change allocation require untouched matched-event panel, positive net expectancy with uncertainty accounted for, gap-aware15minute exits and fresh executable quotes. Patient response rates are not stock win rates. Rates/totals: holdout mean-.094356% implies-.176654USD per187.22 deployment, before fixed operating costs. Hard limits fund187.22, position212.7475, loss budget8.5099; negative edge binds first. Sources https://runway.adityaperswal.workers.dev/data/stock-bars ; https://ir.opusgtx.com/presentations ; https://ir.tyra.bio/static-files/e2ddb459-375e-49f8-a9ae-a5303c6d8e3a ; https://inhibrx.com/hexagon-slides/ . Records1769–1773/lessons555–557. Monitor145 resolved,147 at21UTC;42/127 preserved. Local-tested150 scheduled30min3runs replaces146, cutoff21:10/clamp20UTC; remote lastRun null at19:45, verification pending. 15/84/85 retained. No positions or orders from returned ledger; no orders placed. Completed within planned allowance.

P1 First, clinicalactivitymustreplicate inprespecifiedcontrolleddurability/safety endpoints. Second, successfuldevelopmentmustsecureapproval,payercoverage andfunding/manufacturing. Third, netcashafterdilution mustexceedexpectationsalreadyembeddedinprice. Sponsors/financierscanbenefit beforeexistingshareholders. Alternativechain: attentionimprovesspread, attractslateentry, thenreversalexposes15minexitgaps; IRD-17.33%high isobservedpath, notcausalproof. Strongcounterargumentcontinueddriftpossible; possibilitydoesnotmeetindependentcostededgegate. Sources obs18586/18588–90; https://ir.opusgtx.com/presentations and https://inhibrx.com/hexagon-slides/ .

P1 20000NumPyIIDpaths20drawsfrom3realizedreturns,seed9091230,187.22USD producesPnLpercentiles[-93.669315,-30.013809,79.173517],loss81.26%. P2 Sameinputs reproduceprior1759, notindependentvalidation. Operatorcensoring/N3 invalidate predictive interpretation and cannotestimate15minstop-exitodds. P3 Negativeholdoutmean implies-.176654USD perfullfunddeployment. ConclusionquarterKelly0; actualproposedrisk0. Sourcesquery_trades fund=quant, analysis1642, collector/simulationobservation.

P1 Direct19:42–43threePDFSHA match16:33; no substantivechange incheckedfiles. P2 Priorreview TYRAprimaryCR8/14 versus8/8subgroupORR and modeledHRs; IRDhighlightednonprespecifiedloci versusplannedprespecifiedpivotal; INBXdifferent efficacy/safetydenominators remain unresolved stockvaluation inputs. P3 Sponsorsclosesttoevents butfinanciallyinterested; fileidentitydoesnotproveabsenceofothernews. Counterargument genuineefficacymaycreatevalue, butcontrolleddurability,regulatory/payerfunding andnetdilution bridges remain uncalibrated. No fabricatedDCF orapprovalprobability. Sources https://ir.tyra.bio/static-files/e2ddb459-375e-49f8-a9ae-a5303c6d8e3a ; https://ir.opusgtx.com/presentations ; https://inhibrx.com/hexagon-slides/ ; obs18586.

P1 DelayedSIP through19:25TYRA21.78(+16.7203%open,-18.5185%prior),IRD5.845(+34.6774%prior,-17.3267%high);INBX19:24 114.78(-2.2150%open,-10.7048%high). P2 Returnedminutes349/356/265 of356; missing7/0/91 notfilled. P3 IEX19:42spreads204.94/16.88/2962.83bps; fullfundwholelots8/31/1 crosscost3.52/.31/33.80USD, INBXcrossalone>8.5099risk. Quotesonevenue, delayedbarsnotfills. Conclusion recordbothdirections; narrowIRDspread doesnotestimatewinprobability. Source https://runway.adityaperswal.workers.dev/data/stock-bars and /data/stock-snapshots ; obs18588–90.

P1 Original1642 reread: train2016–20,holdout2021–25,252trades,-21.631824%,DD25.206217%,p45.634921%,cashW.490802%/L.585548%,mean-.09435646%; stress-52.657075%. P2 Extension2026N28+2.31% loses3.26%stress and cannot replace holdout. P3 OwnN3 operatorliquidations p1/3,W7.93994%/L5.26143%,mean-.860974%; censoredhorizons andmissingquote benchmarks prevent exit/slippage inference. Both clippedquarterKelly0. No newbacktest/refit; keepallocation0. Counterexample recentpositiveextension is real but insufficient independent evidence. Source original1642 and query_trades fund=quant; observations18585.

Startcash187.22/account850.99; goalrepeatablepositivecashreturns; bindingconstraint independentlyvalidated net edge. P1 Original1642 negative252tradeholdout,quarterKelly0; no newfit. P2 ThreecensoredrealizedtradesquarterKelly0,priorillustrationreproducednotforecast. P3 PublishedQSSnominalgrowth3.0% andECEClevel+.6223% do notestablishmatchedmargin/constantcompositioninflationsurprise; SPY-.3455%post13:59notcausal. P4 SameclinicalPDFs; IRD+28.69%prior but-21.00%high illustratespathrisk;17.81bpsIEXspreadisnotwinprobability. Conclusionnotional0; noPROPOSE/EXIT/ADJUST/FUND. Validmandatorygate; soundnessconditionalon data/model, notclaim noquantstrategyworks. Strongcounterargument positiveclinicalmomentumorprofitablemacrogrowth mightpersist; requiresuntouchedcostedactualexitstockpanel, not selectedintradayentry. Capsfund187.22,position212.7475,risk8.5099; negativeedgebindsfirst. Recorded1756–1760/lessons549–551. Due60/141resolved,145next19:40;42/127preserved. Tested146scheduled30m8runs replaces142cutoff16:45; remote146unrunat16:37,84last16:00overduenext16:30,coverageuncertainuntilpayloadverified. Preserve15/84/85. Noqueuedorders. Sources https://www.census.gov/services/current/index.html ; https://www.bls.gov/news.release/archives/ecec_09092026.htm ; https://ir.tyra.bio/static-files/e2ddb459-375e-49f8-a9ae-a5303c6d8e3a ; https://ir.opusgtx.com/presentations ; https://runway.adityaperswal.workers.dev/data/stock-bars .

1 Nominalservicesrevenue grows -> firms must retain margin after hours/inputprices -> retainedprofit must convertto freecash -> alreadypricedgrowth must leave expectedstockreturn. ECECcrosspopulationlevels cannotverify marginlink, SPYfall doesnotidentify cause. 2 Clinicalactivity -> prespecifiedcontrolleddurability/safetyreplication -> regulatory/payerfunding/manufacturing -> shareholdercash netdilution. Sponsors benefitfromfinancing before shareholdersnecessarilyearnreturns; unchangedselectedclinicaldata donotclose gaps. 3 LargeIRDinitialmove -> attention/liquidity improves17.81bpsquotedspread -> crowdedlateentries faceretreat(-21%high) -> anunvalidatedstopmayrealizeoutsizedlossbetween15minchecks. Deductionconditional, plausiblemechanismsnotestimatedcausality; retaincash. Sources QSS/ECECprimary releases, https://ir.opusgtx.com/presentations , https://ir.tyra.bio/static-files/e2ddb459-375e-49f8-a9ae-a5303c6d8e3a , /data/stock-bars. Strongcounterargument continueddriftcanoccur; occurrencealoneisnotvalidatedexpectedpayoff.

P1 NumPyseed9091230 20000paths20IIDdrawsfromactual3closedreturnfractions reproduces1740/1706;hypothetical187.22USD PnL2.5/50/97.5[-93.669315,-30.013809,79.173517],loss81.26%. P2 IID/stationarityunsupported,censoredoperatorliquidations; resampling3cannotmanufactureclinicalstockedge. P3 Holdoutmean-.09435646% implies-.176654USD per187.22deployment; grossrepeatabilitynotestablished. Conclusionnotforecastorstop-exitodds; allocation0 becausequarterKelly0. Riskcap8.5099 andfund187.22 arehardconstraints iffutureedgepasses. Obs18550 and simulationobservation; sourcequery_trades fund=quant; savedquant1630/stats.json.

P1 CensusSep9QSS Q2nominalSA6418.7bn vs6231.3bnQ1,+187.4bn;3.0%QoQ(+/-.4),7.6%YoY(+/-.6),advance3.1revised-.1pp. UtilitiesQoQ-1.9%,transport+5.1 showsheterogeneity. P2 BLSJuneECECprivate46.89/hour vsMarchvintage46.60,+.29/.6223%;wages32.82vs32.60+.6748%,benefits14.07vs14.01+.4283%. Levels sensitive to worker composition and differing populations; cannot subtract them from sales growth to infer margin, cannot callECIinflation. Strong nominalactivity/benignconstantcompositioncost jointpremise remainsunproven; expectationsnotmeasured. P3 CurrentTYRA/IRD/INBXPDFhashes identicalprior; modeledHRs remain assumptions/nonprespecifiedloci remainqualifications; no newclinicalfundamentalnews inboundedURLs. Strongcounterargument salesgrowthcouldsupportprofit but prices/hours/mix/financing canabsorbit. NoDCF/clinicalapprovalprobabilityinvented. Sources https://www.census.gov/services/current/index.html ; https://www.bls.gov/news.release/archives/ecec_09092026.htm ; https://www.bls.gov/news.release/archives/ecec_06122026.htm ; clinicalPDFsobs18558.

P1 RawdelayedSIP16:16 TYRA20.925 +12.1383%open but-21.7172%prior; IRD5.585 +28.6866%prior but-21.0042%high7.07; INBX122.85 +7.4427%prior but-4.4266%high. Both directions recorded, no posthocwinningentry. P2 TYRA/IRD/SPY167of167minutes; INBX129of167,38missingnotfilled. P3 SPY761.46 vs13:59 764.10=-.3455%,descriptive notcausal release response. P4 IEX16:32 IRD17.81bps spread improvesexecutiononly; TYRA/INBX affordablecross23.87/33.26USD exceed8.5099risk. Onevenuequotes notNBBO; delayedbarsnotfills; stops15mincannotboundjumps. Conclusion no signal override to failednetedge. Source https://runway.adityaperswal.workers.dev/data/stock-bars and /data/stock-snapshots ; observations18551–57.

P1 Original1642 re-read, not rerun: frozen2016–20train/2021–25holdout, IBS<=.2 nextopen1ADRstop/1.5ADRtargetorclose,fee1bp+slip5bpsside,vectorbt cashcurvereconciled. Holdout252,-21.631824%,DD25.206217%,p45.634921%,cashW.490801991%,L.585547862%,mean-.094356461%; stress-52.657075%. P2 2026extensionN28+2.31%base/-3.26%stress cannot replace holdout. P3 query_trades threeoperatorliquidations p1/3,W7.93994%,L5.26143%,mean-.860974%; censored4–6weektheses, no slippagebenchmarks. Both clippedquarterKelly=max(0,.25*(p-(1-p)*L/W))=0. Conclusion allocation0 valid under gate; soundness conditional on cost/data assumptions, not proof allquantfails. Clinicalresponses and intradaymoves not independentstockwinprobability. Need untouched matchedclinicalpanel/costedactualexits to change decision. Obs18550/18558; source https://runway.adityaperswal.workers.dev/data/stock-bars and query_trades fund=quant.

StartQuantcash187.22/account850.99; goalrepeatablepositivecashreturns; bindingconstraintindependentnetedge. P1 Re-readfrozenbacktest1642:252EEMholdouttrades-21.6318%,stress-52.6571%,p45.6349%,cashW.490802%/L.585548%,quarterKelly0; all8main/all72stressfail per1690. No newstrategyfit/backtestclaimed. P2 OwnN3operatorliquidationsquarterKelly0,nonpredictiveresamplingreproduces1706. P3 FirstopenTYRA-30.19%,IRD+22.12%;13:52IRD+57.03%and29bpsspreadimprovesexecutionbutnotstockprobability. P4 CurrentTYRA31pagedeckrecovered:legacyitem21wrongyear,HR/DFSprojectionsmodeled,sponsorsurveysnotcash; IRDnonprespecifiedloci,INBXunchanged. ConclusionnoPROPOSE/EXIT/ADJUST/FUND,notional0; mandatorygatevalid,soundnessconditionalonproviderandmodel,notclaimallquantfails. Strongcounterargumentpositiveclinicalnews/narrowspreadcouldsupportdrift; requiresuntouchedcostedclinicalpanel/exits,notoneeventorrescuevariant. Analyses1737–1741,obs18501/03/05/18/19/25–28,lessons537–539. Monitor134resolved,next16:30clinicalsuccessorcreated;60/42/127retained. Truncated137cancelled,tested142scheduled30m7runs/hard16:45;13:58lastRun null meansremoteexecutionUNVERIFIED,localall3/footerpassed. Preserve15/84/85. GapsQ&A,liveSIP403,independentstockholdout/15minfills/unconditionalIRDfunding. Fullslidesgapresolved. Finalrecordphase13:57(~7min);completedunder33minplan/45hard. Sources https://ir.tyra.bio/static-files/e2ddb459-375e-49f8-a9ae-a5303c6d8e3a ; https://ir.opusgtx.com/presentations ; https://runway.adityaperswal.workers.dev/data/stock-bars .

1 TYRAoraltreatmentmayreduceproceduralburden; thencontrolledadjuvanttrialmustestablishdurablerecurrencebenefit; thenapproval,payerpricing,manufacturingandfundingmustconvertsalesintoequitycash. Survey38patientsand51urologists supportsinterestonly; fullpenetration>$5bnnotachievedcash. Sponsors/patientsbenefitfromdevelopment; financerscanbenefitwhileexistingholdersarediluted. 2 IRDfunctionalchangesmayadvancepivotaldesign; thenprespecifiedlociandrandomizedcomparisonmustreplicate; thenmanufacturing/funding/payersdeterminecapture. Nonprespecifiedcohortlociareexplicitcounterexampletoclaimcurrenttrialalreadysatisfiesfuturepivotalendpoint. 3 Strongpriceactionmayattractmomentumflows; thenliquiditycanimprovespread; thenlateentrantsmayfacecrowding/reversal. IRD29bpsspreadsupportssecondlinkonly,notpositivefutureexpectancy. Deductionvalid,mechanismsconditional; independentstockpayoffmissing. Source https://ir.tyra.bio/static-files/e2ddb459-375e-49f8-a9ae-a5303c6d8e3a ; https://ir.opusgtx.com/presentations . NoDCF/approvalprobabilityfabricated.

1 Re-run1706NumPyseed9091230 with actualthreeclosedreturnfractions[-.0539236448052,.0793994130743,-.0513049904703],20000paths20IIDdraws,compoundhypothetical187.22USD. P&L2.5/50/97.5pct[-93.669315,-30.013809,79.173517];loss81.26%. Reproducesoldresult,notnewtest. 2 IID/stationarity/executionunsupportedN3operatorliquidations. Resampling cannotgenerate missing independentinformation; donotinterpret81.26%asclinicaltradelossprobability. 3 ObservedquarterKelly0proposedUSD0; noassumed stop/targetorMonteCarloexitoddswithoutqualifiedrule. Hardconstraintsfund187.22,accountcap212.7475,risk8.5099 furtherlimit anyfuturepositiveedge. Source query_trades fund=quant IDs9/7/1; observations18528; prior1706. Validillustrationconditionalonexplicitunsupportedassumptions; cannotjustifyrisk.

1 Originalbacktest1642re-read,reusedNOT rerun: frozen2016–20train/2021–25holdout; IBS<=.2nextopen,1ADRstop/1.5ADRtargetorclose;fee1bp+slip5bpsside. EEM252holdoutreturn-21.6318%,DD25.2062%,p45.6349%,cashavgwin.490802%,loss.585548%,quarterKelly0;16bpssidestress-52.6571%. All8main/all72stresscellsnegative per1690. 2 Recomputequery_tradesIDs9/7/1:N3p1/3,avgwin7.93994%,loss5.26143%,mean-.860974%; quarterKellymax(0,.25*(p-(1-p)*L/W))=0. Operatorliquidationscensor4–6weektheses; noidentifiedslippageorstop/targethitrates. 3 ClinicalN14/N5andthreestocksselectedforeventsarenotstockwinprobability. Neitherpositive2026extension(base2.31%,stress-3.26%N28)norIRDtoday canreplacefailedholdout. Newuntouchedindependentclinicalpricepanelwithexactentries/costs/exitscouldmoveallocation; onepricecannot. Sources query_trades fund=quant ; https://runway.adityaperswal.workers.dev/data/stock-bars . Obs18528.

1 FrozenSep8SIPcloses26.73/4.34/114.34. Direct13:52delayedSIPfirst13:30minuteopensTYRA18.66(-30.1908%),IRD5.30(+22.1198%),INBX117.38(+2.6587%). Last13:36TYRA19.17/IRD6.13;INBX13:35 121.76. 7/7/6bars no pagination; boundary/missingnotfilled. 2 IEX13:52trades19.57/6.815/125.425 imply-26.7864/+57.0276/+9.6948%vspriorSIP; distinctfeeds/timesnotfills. IRDspread29.37bps from6.80/6.82 materiallyimprovesprior629bps;27shares184.14crosscost.54 versusTYRA9sharescross11.88 andINBX1share19.94, bothabove8.5099risk. These quotedcrossesillustrative notNBBO/fills. LiveSIP403. 3 Reboundandcontinuationretained equally; neitherselectsnewrule. Nominalstopcannotboundgap/15minlatency. Source https://runway.adityaperswal.workers.dev/data/stock-bars ; https://runway.adityaperswal.workers.dev/data/stock-snapshots . Obs18501/03/05. Bindinggateindependentcostedclinicalstockedgeabsent; size0.

1 Currentir.tyra.bioevent yielded31pageSep9dataPDF; legacyitem21wasJune2023,correct18519/1709. p7primary3moCR;60mg8/14 differs8/8singlemarkerORR. p18PK172pooledsubjectsnottrialefficacyN172. p20DFS24m55/72/81% andHR.6/.3/.2 areexplicitillustrative assumptions,notobservedrandomizedhazardratios. 2 Augsponsorsurveys38patients/51urologists suggestconvenienceappeal,notrepresentativeuptake/paidprescriptions. >$5bnfullpenetrationmarket doesnotestimaterevenueorDCF; timelines2027/FDAfeedbackpending. 3 IRD36slidesp20/22/26reconfirmnonprespecifiedloci;threepatientgainsnotpivotalproof. INBXfullPDFshashesunchanged. Bullcounterexample:oralconvenienceandstrongfuturecontrolleddata couldcreaterealvalue; currentdata cannotquantifyapprovaloddsorremainingstockreturn. Sourceclosestissuerbutinterested; release/deck/surveynotindependentsources. Sources https://ir.tyra.bio/static-files/e2ddb459-375e-49f8-a9ae-a5303c6d8e3a ; https://ir.opusgtx.com/presentations ; https://inhibrx.com/hexagon-slides/ . Obs18518/25–27. Verdictclinicalwatch,stocksize0.

Start187.22USDQuantcash,850.99account;goalrepeatablepositivecashreturns;bindingconstraintvalidatednetedge. P1 Re-readoriginalbacktest1642:2016–20training,2021–25holdout,nextopenIBS<=.2with1ADRstop/1.5ADRtargetorclose,1bpfee+5bpslippageeachside. EEM252holdoutreturn-21.6318%,DD25.2062%,p45.6349%,cashavgwin.490802%/loss.585548%,Kelly0;16bpssidestress-52.6571%. All8primaryholdouts/all72stresscellslose. No fresh optimization orborrowedpositive2026extension; recorded backtest re-used,NOT rerun. P2 Clinicalsource1703findsTYRAprimary8/14differentheadline8/8;IRDfullslidesnonprespecifiedloci/conditionalfunding;INBXunchanged. P3 Technical1707recordsTYRA-34.53%/IRD+12.56%delayedpremarket;neitherdirectionestablishesindependentstockdrift,quotesstale/wideand15minexitmodelabsent. P4 Owntrade1705N3censoredoperatorliquidationsKelly0;simulation1706illustrativeonly. ConclusionnoPROPOSE/EXIT/ADJUST/FUND. Deductionvalidundermandate;source/providerqualityconditional,notclaimallquantstrategiesfail. Counterargumentcheapexecutionorclinicalbreakthroughcouldgenerateedge,butcannotrepairfailedtestorunmeasuredtradepayoffwithoutnewindependentvalidation. Resolve47/48/121;successor134at13:50coversclinicalfullsources/regularopen,job137bounded15m7runsuntil14:15hardcutoff. Preserve15/84/85/131and60/42/127. Ledgerzeroallstatusesreverified12:39. Finalrecordphasebegan12:37,overall~9minatdecision;under35plan/45hard. GapsTYRAfullslides/webcastnotretrieved(exacteventURL200butnolinks),independentFDAminutes,unconditionalIRDfunding,liveSIPentitlement403,untouchedclinicalpriceholdout. Allgapsretainzeroallocation. Sources https://runway.adityaperswal.workers.dev/data/stock-bars ; https://clinicaltrials.gov/api/v2/studies/NCT06995677 ; https://ir.opusgtx.com/presentations ; https://inhibrx.com/hexagon-slides/ . Lessons522–524; observations18376–18401/18449–51; analyses1703/1705–1708.

Startclinicalproof-of-concept,goalrepeatablecashstockedge,bindingconstraintindependentcostedstockpayoff. Chain1:TYRAoralactivitymayimprovetreatmentacceptance;thenadjuvantcontrolledtrialmustdemonstraterecurrencebenefitanddurability;thenapproval/adoption/reimbursementmustproducecashabovecontinueddevelopment/dilution. Counterexamplescatheteravoidancedoesnotproveefficacy,activityinselectedmarkerlesionsdoesnotmeasureadjuvantrecurrence. Chain2:IRDlocalizedvisiongainsmayjustifyearlier-stageenrollment;thenprespecifiedloci+PROrandomizedpivotaltestmustreplicatewithcommercialmanufacturing;thenfundingconditionsandpayeraccessdetermineequityvalue. Counterexamplenonprespecifiedlociand5differentpatientsinflatesapparentconsistency;cash2029projectionincludespotentialcredit. Patients/sponsors/investorsmaybenefit;furtherfundraisingalsobenefitscashrunwaybutdilutesexistingowners. Bothvalidmechanismchainsarehypotheses,numericalstockprobabilityunidentified. Strongbullcasefuturetrialsuccesscouldrevaluefirms; current+12.56%IRDand-34.53%TYRAonlyshowoppositerepricing,notcausaldemonstrationorremainingalpha. Sources https://tyrabio.investorroom.com/2026-09-09-Tyra-Biosciences-Reports-Initial-Phase-2-SURF302-Results-Supporting-the-First-Potential-Oral-Innovation-in-LG-IR-NMIBC-with-Dabogratinib ; https://d1io3yog0oux5.cloudfront.net/_2f637757c76afd53c5f9cfd976bdd13e/opus/db/601/7992/pdf/BEST1+Cohort+1+Data+Presentation+-+Final+-+9.09.26.pdf ; https://ir.opusgtx.com/press-releases/detail/540/opus-genetics-announces-financial-results-for-second-quarter-2026-and-provides-corporate-update .

P1 FreezeSep8rawSIPproviderdailyTYRA26.73/IRD4.34/INBX114.34. Sep9delayed12:20minutes17.50/4.885;firstpost11UTCopens26.96/4.35arewithinnewsminuteandnotassumedfills. TYRA-34.53%,IRD+12.56%vspriorclose; bothoutcomesretained. INBXonly08:26bar118.01isold,nocurrentreactionclaim. P2 IEXTYRAask0andprior-dayquote;INBX94.6/134.6prior-dayquote;IRD12:29quote4.77/5.08,629.44bps. LiveSIP403. AtIRDask36shares182.88cash,cross-spread11.16 exceedsaccount1%8.5099; smallerlotdoesnotcreateedge. P3 Noindependentcostedclinicalstockruleor15minuteexits; cannotturnTYRAselloffintomeanreversionorIRDriseintomomentumfromoneevent. No newbacktest selected afterseeingoutcome. Cashretained;bounded137collectsprospectivereactionthroughnext13:50review,last20/firstregular5notfullarchive. Sources https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=TYRA,IRD,INBX&timeframe=1Min&feed=sip&adjustment=raw ; https://runway.adityaperswal.workers.dev/data/stock-snapshots?symbols=TYRA,IRD,INBX&feed=iex . Observations18384–86,18397,18399,18449–51.